Research ArticleOriginal Article

A novel recurrence-associated metabolic prognostic model for risk stratification and therapeutic response prediction in patients with stage I lung adenocarcinoma

Chengming Liu, Sihui Wang, Sufei Zheng, Xinfeng Wang, Jianbin Huang, Yuanyuan Lei, Shuangshuang Mao, Xiaoli Feng, Nan Sun and Jie He
Cancer Biology & Medicine August 2021, 18 (3) 734-749; DOI: https://doi.org/10.20892/j.issn.2095-3941.2020.0397

References

  1. 1.↵
    2. Siegel RL,
    3. Miller KD,
    4. Jemal A.
    Cancer statistics, 2019. CA Cancer J Clin. 2019; 69: 7–34.
    OpenUrlCrossRefPubMed
  2. 2.↵
    2. Chen Z,
    3. Fillmore CM,
    4. Hammerman PS,
    5. Kim CF,
    6. Wong KK.
    Non-small-cell lung cancers: a heterogeneous set of diseases. Nat Rev Cancer. 2014; 14: 535–46.
    OpenUrlCrossRefPubMed
  3. 3.↵
    2. Tanoue LT,
    3. Tanner NT,
    4. Gould MK,
    5. Silvestri GA.
    Lung cancer screening. Am J Respir Crit Care Med. 2015; 191: 19–33.
    OpenUrlCrossRefPubMed
  4. 4.
    2. Wood DE,
    3. Kazerooni EA,
    4. Baum SL,
    5. Eapen GA,
    6. Ettinger DS,
    7. Hou L, et al.
    Lung cancer screening, version 3.2018, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2018; 16: 412–41.
    OpenUrlAbstract/FREE Full Text
  5. 5.↵
    2. Goldstraw P,
    3. Chansky K,
    4. Crowley J,
    5. Rami-Porta R,
    6. Asamura H,
    7. Eberhardt WE, et al.
    The IASLC lung cancer staging project: proposals for revision of the TNM stage groupings in the forthcoming (eighth) edition of the TNM classification for lung cancer. J Thorac Oncol. 2016; 11: 39–51.
    OpenUrlCrossRefPubMed
  6. 6.↵
    2. Tsao AS,
    3. Scagliotti GV,
    4. Bunn Jr PA,
    5. Carbone DP,
    6. Warren GW,
    7. Bai C, et al.
    Scientific advances in lung cancer 2015. J Thorac Oncol. 2016; 11: 613–38.
    OpenUrlCrossRefPubMed
  7. 7.↵
    2. Ettinger DS,
    3. Aisner DL,
    4. Wood DE,
    5. Akerley W,
    6. Bauman J,
    7. Chang JY, et al.
    NCCN guidelines insights: non-small cell lung cancer, version 5.2018. J Natl Compr Canc Netw. 2018; 16: 807–21.
    OpenUrlAbstract/FREE Full Text
  8. 8.↵
    2. Fujimoto T,
    3. Cassivi SD,
    4. Yang P,
    5. Barnes SA,
    6. Nichols FC,
    7. Deschamps C, et al.
    Completely resected N1 non-small cell lung cancer: factors affecting recurrence and long-term survival. J Thorac Cardiovasc Surg. 2006; 132: 499–506.
    OpenUrlCrossRefPubMedWeb of Science
  9. 9.↵
    2. Pignon JP,
    3. Tribodet H,
    4. Scagliotti GV,
    5. Douillard JY,
    6. Shepherd FA,
    7. Stephens RJ, et al.
    Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol. 2008; 26: 3552–9.
    OpenUrlAbstract/FREE Full Text
  10. 10.↵
    2. Sangha R,
    3. Price J,
    4. Butts CA.
    Adjuvant therapy in non-small cell lung cancer: current and future directions. Oncologist. 2010; 15: 862–72.
    OpenUrlAbstract/FREE Full Text
  11. 11.↵
    2. Yang Y,
    3. Mao Y,
    4. Yang L,
    5. He J,
    6. Gao S,
    7. Mu J, et al.
    Prognostic factors in curatively resected pathological stage I lung adenocarcinoma. J Thorac Dis. 2017; 9: 5267–77.
    OpenUrl
  12. 12.↵
    2. Saynak M,
    3. Veeramachaneni NK,
    4. Hubbs JL,
    5. Nam J,
    6. Qaqish BF,
    7. Bailey JE, et al.
    Local failure after complete resection of N0-1 non-small cell lung cancer. Lung Cancer. 2011; 71: 156–65.
    OpenUrlCrossRefPubMedWeb of Science
  13. 13.↵
    2. Hanahan D,
    3. Weinberg RA.
    Hallmarks of cancer: the next generation. Cell. 2011; 144: 646–74.
    OpenUrlCrossRefPubMedWeb of Science
  14. 14.↵
    2. Peng X,
    3. Chen Z,
    4. Farshidfar F,
    5. Xu X,
    6. Lorenzi PL,
    7. Wang Y, et al.
    Molecular characterization and clinical relevance of metabolic expression subtypes in human cancers. Cell Rep. 2018; 23: 255–69.e4.
    OpenUrlCrossRefPubMed
  15. 15.↵
    2. DeBerardinis RJ,
    3. Chandel NS.
    Fundamentals of cancer metabolism. Sci Adv. 2016; 2: e1600200.
  16. 16.↵
    2. Vander Heiden MG,
    3. DeBerardinis RJ.
    Understanding the intersections between metabolism and cancer biology. Cell. 2017; 168: 657–69.
    OpenUrlCrossRefPubMed
  17. 17.↵
    2. Chen PH,
    3. Cai L,
    4. Huffman K,
    5. Yang C,
    6. Kim J,
    7. Faubert B, et al.
    Metabolic diversity in human non-small cell lung cancer cells. Mol Cell. 2019; 76: 838–51.e5.
    OpenUrlCrossRefPubMed
  18. 18.↵
    2. Woo T,
    3. Okudela K,
    4. Yazawa T,
    5. Wada N,
    6. Ogawa N,
    7. Ishiwa N, et al.
    Prognostic value of KRAS mutations and Ki-67 expression in stage I lung adenocarcinomas. Lung Cancer. 2009; 65: 355–62.
    OpenUrlPubMed
  19. 19.↵
    2. Kim P,
    3. Cheng F,
    4. Zhao J,
    5. Zhao Z.
    ccmGDB: a database for cancer cell metabolism genes. Nucleic Acids Res. 2016; 44: D959–68.
    OpenUrlCrossRefPubMed
  20. 20.↵
    2. Long J,
    3. Wang A,
    4. Bai Y,
    5. Lin J,
    6. Yang X,
    7. Wang D, et al.
    Development and validation of a TP53-associated immune prognostic model for hepatocellular carcinoma. EBioMedicine. 2019; 42: 363–74.
    OpenUrl
  21. 21.
    2. Liu C,
    3. Zheng S,
    4. Jin R,
    5. Wang X,
    6. Wang F,
    7. Zang R, et al.
    The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity. Cancer Lett. 2019; 470: 95–105.
    OpenUrl
  22. 22.↵
    2. Alsaleem MA,
    3. Ball G,
    4. Toss MS,
    5. Raafat S,
    6. Aleskandarany M,
    7. Joseph C, et al.
    A novel prognostic two-gene signature for triple negative breast cancer. Mod Pathol. 2020; 33: 2208–20.
    OpenUrlCrossRef
  23. 23.↵
    2. Newman AM,
    3. Liu CL,
    4. Green MR,
    5. Gentles AJ,
    6. Feng W,
    7. Xu Y, et al.
    Robust enumeration of cell subsets from tissue expression profiles. Nat Methods. 2015; 12: 453–7.
    OpenUrlCrossRefPubMed
  24. 24.↵
    2. Gentles AJ,
    3. Newman AM,
    4. Liu CL,
    5. Bratman SV,
    6. Feng W,
    7. Kim D, et al.
    The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med. 2015; 21: 938–45.
    OpenUrlCrossRefPubMed
  25. 25.↵
    2. Jiang P,
    3. Gu S,
    4. Pan D,
    5. Fu J,
    6. Sahu A,
    7. Hu X, et al.
    Signatures of T cell dysfunction and exclusion predict cancer immunotherapy response. Nat Med. 2018; 24: 1550–8.
    OpenUrlPubMed
  26. 26.↵
    2. Geeleher P,
    3. Cox N,
    4. Huang RS.
    pRRophetic: an R package for prediction of clinical chemotherapeutic response from tumor gene expression levels. PLoS One. 2014; 9: e107468.
  27. 27.↵
    2. Geeleher P,
    3. Cox NJ,
    4. Huang RS.
    Clinical drug response can be predicted using baseline gene expression levels and in vitro drug sensitivity in cell lines. Genome Biol. 2014; 15: R47.
    OpenUrlCrossRefPubMed
  28. 28.↵
    2. Rody A,
    3. Holtrich U,
    4. Pusztai L,
    5. Liedtke C,
    6. Gaetje R,
    7. Ruckhaeberle E, et al.
    T-cell metagene predicts a favorable prognosis in estrogen receptor-negative and HER2-positive breast cancers. Breast Cancer Res. 2009; 11: R15.
    OpenUrlCrossRefPubMed
  29. 29.↵
    2. Hanzelmann S,
    3. Castelo R,
    4. Guinney J.
    GSVA: gene set variation analysis for microarray and RNA-seq data. BMC Bioinformatics. 2013; 14: 7.
    OpenUrlCrossRefPubMed
  30. 30.↵
    2. Schildberg FA,
    3. Klein SR,
    4. Freeman GJ,
    5. Sharpe AH.
    Coinhibitory pathways in the B7-CD28 ligand-receptor family. Immunity. 2016; 44: 955–72.
    OpenUrlPubMed
  31. 31.
    2. Wang J,
    3. Sanmamed MF,
    4. Datar I,
    5. Su TT,
    6. Ji L,
    7. Sun J, et al.
    Fibrinogen-like protein 1 is a major immune inhibitory ligand of LAG-3. Cell. 2018; 176: 334–47.e12.
    OpenUrl
  32. 32.
    2. Chen L,
    3. Flies DB.
    Molecular mechanisms of T cell co-stimulation and co-inhibition. Nat Rev Immunol. 2013; 13: 227–42.
    OpenUrlCrossRefPubMed
  33. 33.↵
    2. Limagne E,
    3. Richard C,
    4. Thibaudin M,
    5. Fumet JD,
    6. Truntzer C,
    7. Lagrange A, et al.
    Tim-3/galectin-9 pathway and mMDSC control primary and secondary resistances to PD-1 blockade in lung cancer patients. Oncoimmunology. 2019; 8: e1564505.
  34. 34.↵
    2. Black WC,
    3. Gareen IF,
    4. Soneji SS,
    5. Sicks JD,
    6. Keeler EB,
    7. Aberle DR, et al.
    Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med. 2014; 371: 1793–802.
    OpenUrlCrossRefPubMedWeb of Science
  35. 35.↵
    2. Suzuki K,
    3. Kadota K,
    4. Sima CS,
    5. Nitadori J,
    6. Rusch VW,
    7. Travis WD, et al.
    Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor interleukin-12 receptor beta2 (IL-12Rbeta2), IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013; 31: 490–8.
    OpenUrlAbstract/FREE Full Text
  36. 36.↵
    2. Hensley CT,
    3. Faubert B,
    4. Yuan Q,
    5. Lev-Cohain N,
    6. Jin E,
    7. Kim J, et al.
    Metabolic heterogeneity in human lung tumors. Cell. 2016; 164: 681–94.
    OpenUrlCrossRefPubMed
  37. 37.↵
    2. Faubert B,
    3. Li KY,
    4. Cai L,
    5. Hensley CT,
    6. Kim J,
    7. Zacharias LG, et al.
    Lactate metabolism in human lung tumors. Cell. 2017; 171: 358–71.e9.
    OpenUrlCrossRefPubMed
  38. 38.↵
    2. Monaco ME.
    Fatty acid metabolism in breast cancer subtypes. Oncotarget. 2017; 8: 29487–500.
    OpenUrlCrossRef
  39. 39.↵
    2. Zhang H,
    3. Zou J,
    4. Yin Y,
    5. Zhang B,
    6. Hu Y,
    7. Wang J, et al.
    Bioinformatic analysis identifies potentially key differentially expressed genes in oncogenesis and progression of clear cell renal cell carcinoma. PeerJ. 2019; 7: e8096.
  40. 40.↵
    2. Niu Z,
    3. Shi Q,
    4. Zhang W,
    5. Shu Y,
    6. Yang N,
    7. Chen B, et al.
    Caspase-1 cleaves PPARγ for potentiating the pro-tumor action of TAMs. Nat Commun. 2017; 8: 766.
  41. 41.↵
    2. Hao Y,
    3. Kong X,
    4. Ruan Y,
    5. Gan H,
    6. Chen H,
    7. Zhang C, et al.
    CDK11p46 and RPS8 associate with each other and suppress translation in a synergistic manner. Biochem Biophys Res Commun. 2011; 407: 169–74.
    OpenUrlPubMed
  42. 42.↵
    2. Jønson L,
    3. Vikesaa J,
    4. Krogh A,
    5. Nielsen LK,
    6. Hansen T,
    7. Borup R, et al.
    Molecular composition of IMP1 ribonucleoprotein granules. Mol Cell Proteomics. 2007; 6: 798–811.
    OpenUrlAbstract/FREE Full Text
  43. 43.↵
    2. Ruggero D,
    3. Pandolfi PP.
    Does the ribosome translate cancer? Nat Rev Cancer. 2003; 3: 179–92.
    OpenUrlCrossRefPubMedWeb of Science
  44. 44.↵
    2. Holcik M,
    3. Sonenberg N.
    Translational control in stress and apoptosis. Nat Rev Mol Cell Biol. 2005; 6: 318–27.
    OpenUrlCrossRefPubMedWeb of Science
  45. 45.↵
    2. O’Neill LA,
    3. Kishton RJ,
    4. Rathmell J.
    A guide to immunometabolism for immunologists. Nat Rev Immunol. 2016; 16: 553–65.
    OpenUrlCrossRefPubMed
Back to top

In this issue

Print
Download PDF
Email Article
Citation Tools

Jump to section

Keywords